clinical trial · NCT07076290
A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD
COPD (Chronic Obstructive Pulmonary Disease)COPD ExacerbationCOPD Exacerbation AcuteR-3750
brief summary
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-3750) in patients with mild to moderate chronic obstructive pulmonary disease (COPD)
started
Sep 1, 2026
primary completion
Apr 30, 2028
completion
Dec 31, 2028
last updated
Jan 29, 2026
detailed description
Patients will take an oral dosage of probiotic (R-3750) and provide patient-reported and scored measure of their chronic obstructive pulmonary disease (COPD). Blood and fecal evaluations of inflammation and assessment of probiotic (R-3750) on fecal levels will also be measured.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol